Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Home
Response to Treatment With nab-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
Next Post
Previous Post
Response to Treatment With
nab
-Sirolimus Among Patients With Primary Uterine PEComa: A Subanalysis From AMPECT
March 26, 2023
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
nab
-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Read More
Emma Reeve
Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update
New Drug Trial Gives Hope for Treatment-Resistant Epilepsy
Baiteng Zhao, PhD
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
Solid Tumors Harboring Pathogenic Inactivating Alterations in
TSC1
or
TSC2
Genes (PRECISION 1)
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.